Anxiety is a constant and excessive worry about future events and fear which is hard to control and lead to considerable impairment or distress. These feelings may cause physical symptoms, such as a fast heart rate. There are a number of anxiety disorders such as generalized anxiety disorder, social anxiety disorder, specific phobia, agoraphobia, and separation anxiety disorder. People often have more than one anxiety disorder. Effective treatments for general anxiety disorder are psychotherapy and medications.
CLICK HERE FOR FREE SAMPLE COPY OF REPORT
According to the Zion Market Research, the U.S. demand for general anxiety disorder market was valued at USD 3,251 million in 2014 and is expected to generate revenue of USD 3,775 million by end of 2020, growing at a CAGR of 2.4% between 2015 and 2020. Anxiety disorder market is expected to witness significant growth in the near future. The anxiety disorder market is mainly driven by rising geriatric population and growing prevalence of anxiety disorders & depression. According to anxiety and depression association of America, general anxiety disorder affects around 3.0% of the U.S. population or about 6.8 million adults, in any given year. Moreover, the presence of favorable government policies and availability of different branded formulations in the U.S. is another key driving factor for anxiety disorder market. However, the weak pipeline of novel drugs may hamper the market growth in the years to come. Nonetheless, development of herbal remedies is expected to open up new growth opportunities in the years to come.
Browse detail report with in-depth TOC @ https://www.zionmarketresearch.com/toc/general-anxiety-disorder-market
Based on therapeutic, anxiety disorder market can be segmented into antidepressant, benzodiazepines, and other therapeutics. The antidepressant was the leading segment and it’s accounted for over 38% market share of total revenue generated in 2014. Various types of medications used to treat general anxiety disorder. Antidepressants such as selective serotonin reuptake inhibitor (SSRI) classes and serotonin-norepinephrine reuptake inhibitor (SNRI) are the first-line medication treatments. Thus, an antidepressant segment is expected to show significant growth in the years to come. Benzodiazepine is a key outlet of anxiety disorder market and is expected to witness exponential growth within the forecast period. Benzodiazepines are highly efficient in reducing muscular tension, promoting relaxation and other physical symptoms of anxiety.
General anxiety market is highly competitive in nature owing to the presence of both large and small pharmaceutical companies. Eli Lilly and Company, Sanofi S.A. Forest Laboratories, Inc., Johnson & Johnson H. Lundbeck A/S, Merck & Co., Inc., Pfizer, Inc. are some of the dominant players in the market space